Literature DB >> 10365138

Renal cell carcinoma: immunohistological investigation of expression of the integrin alpha v beta 3.

H W Wechsel1, E Petri, G Feil, H J Nelde, K H Bichler, W Loesr.   

Abstract

alpha v beta 3 Integrin has been shown in various tumor entities to promote binding to superficial structures of the basement membrane during metastasis. The goal of the present paper was a structural demonstration of this Integrin in renal cell carcinoma (RCC). After removal of paraffin from formalin-fixed tissue, the cells were labelled with the antibody (VNR 147, H. Biermann, Bad Nauheim) using the peroxidase-antiperoxidase method (DAKO Diagnostical GmbH, Hamburg). Evaluation was carried out microscopically and semiquantitatively from missing (-) through moderate (+) to strong (+2) staining. A total of n = 79 RCCs and n = 53 healthy areas were examined. Semiquantitative staining results: there was a grading-dependent increase (+2) of stainability and thus alpha v beta 3 expression. Two of 53 benign specimens showed strong staining, 11 of 53, only weak staining. Four of 18 G1 RCCs showed strong staining, 11 of 18 only weak staining. Results for G2-RCCs: 11 with strong staining, 21 of 40 with weak staining. G3-RCCs: 4 with strong staining, 2 of 7 with weak staining. Of the metastases, on the other hand, 2 of 14 showed strong staining, another 8 of 14 only weak staining. There were no deviations within the histologic (clear-cell, chromophil, or chromophobe) subpopulations. This grading-dependent expression permits the conclusion that the probability of binding to the human basement membrane mediated by alpha v beta 3 Integrin rises with increasing grading, but the already metastatic cell exhibited this Integrin less strongly, since a basement membrane adhesion is no longer necessary for this cell group.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10365138

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Improving gene transfer in human renal carcinoma cells: Utilization of adenovirus vectors containing chimeric type 5 and type 35 fiber proteins.

Authors:  Bishnu Acharya; Shuji Terao; Toru Suzuki; Michio Naoe; Katsuyuki Hamada; Hiroyuki Mizuguchi; Akinobu Gotoh
Journal:  Exp Ther Med       Date:  2010-05-01       Impact factor: 2.447

2.  Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.

Authors:  Catherine Delbaldo; Eric Raymond; Karina Vera; Luz Hammershaimb; Karen Kaucic; Stéphanie Lozahic; Michel Marty; Sandrine Faivre
Journal:  Invest New Drugs       Date:  2007-09-18       Impact factor: 3.850

3.  Comparing the expression of integrins αvβ3, αvβ5, αvβ6, αvβ8, fibronectin and fibrinogen in human brain metastases and their corresponding primary tumors.

Authors:  Jens Schittenhelm; Annemarie Klein; Marcos S Tatagiba; Richard Meyermann; Falko Fend; Simon L Goodman; Bence Sipos
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

4.  [¹⁸F]fluciclatide in the in vivo evaluation of human melanoma and renal tumors expressing αvβ 3 and α vβ 5 integrins.

Authors:  Esther Mena; Rikard Owenius; Baris Turkbey; Richard Sherry; Gennady Bratslavsky; Sven Macholl; Matthew P Miller; Ed J Somer; Liza Lindenberg; Stephen Adler; Joanna Shih; Peter Choyke; Karen Kurdziel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-06-28       Impact factor: 9.236

Review 5.  Radiolabeled antibodies in renal cell carcinoma.

Authors:  Alexander B Stillebroer; Egbert Oosterwijk; Wim J G Oyen; Peter F A Mulders; Otto C Boerman
Journal:  Cancer Imaging       Date:  2007-11-19       Impact factor: 3.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.